NDAORALTABLET
Approved
May 2009
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
7/8 — Comprehensive
CYCLOSET (bromocriptine mesylate) by Aurobindo Pharma is mesylate, a sympatholytic, dopamine d2 receptor agonist. Approved for type 2 diabetes mellitus, type 1 diabetes, diabetic ketoacidosis. First approved in 2009.
Drug data last refreshed 19h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CYCLOSET (bromocriptine mesylate) is an oral dopamine D2 receptor agonist approved in 2009 for type 2 diabetes, type 1 diabetes, and diabetic ketoacidosis. Administered as a timed morning dose, it increases insulin sensitivity and glucose disposal while reducing fasting and postprandial hyperglycemia without elevating plasma insulin levels. This unique sympatholytic mechanism differentiates it from incretin-based and insulin secretagogue competitors.
$3MPart D
Peak5.7 years to LOEAt peak lifecycle with modest Part D claims (3,358 in 2023), this is a niche, stable product with limited team growth—suited for specialists in mature portfolio management rather than launch-phase expansion.
Mechanism of Action
mesylate, a sympatholytic, dopamine D2 receptor agonist. In patients with type 2 diabetes, timed morning administration of CYCLOSET is associated with increased insulin sensitivity and glucose disposal and reduced fasting and postprandial hyperglycemia throughout the meals of the day without…
Indications (3)
Worked on CYCLOSET at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.